Lactose Intolerance Treatment Market Overview
Lactose Intolerance Treatment Market share register 26.12 Billion USD in 2030, projected to grow 5.90% CAGR during the forecast period (2023 - 2030). As per MRFR analysis, the Lactose Intolerance Treatment Market Industry size is expected to grow from 26.12 Billion USD in 2030 to 26.12 Billion USD by 2030.
Top leading companies may be investing in research to improve the efficacy and delivery of lactase enzyme supplements or exploring new treatment approaches for lactose intolerance. Abbott Laboratories, Quest Diagnostics, Labcorp, and others providing diagnostic tools and lactase enzyme supplements. Research and development in areas like enzyme supplements, gene therapy, and microbiome-based treatments are creating new possibilities.
Lactose Intolerance Treatment Market Trends
Lactose intolerance is a medical condition identified by lactase (lactose digesting enzyme) deficiency within the patient’s body. As a result, lactose remains intact and unabsorbed producing various ill-effects such as flatulence, bloating, and abdominal pains. Four types of lactose intolerances are identified, namely, primary lactase deficiency, secondary lactase deficiency, congenital lactase deficiency, and developmental lactase deficiency. Secondary lactase deficiency mainly occurs due toÂ
irritable bowel syndrome (IBS), gastroenteritis, Crohn's disease, ulcerative colitis, celiac disease, chemotherapy, and antibiotics. As per the study by the Journal of Health, Population, and Nutrition in 2017, the prevalence of lactose intolerance was significantly higher in IBS-D patients compared to healthy individuals. In this study, some eligible IBS-D patients and healthy individuals were enrolled. In the enrolled individuals, lactose malabsorption was diagnosed by a lactose hydrogen breath test (HBT), and lactose intolerance-related symptoms were monitored for eight hours following lactose administration.
It was found that the prevalence of lactose malabsorption was 72% in IBS patients and 60% in healthy individuals.
A study published in the Advances in Clinical and Experimental Medicine in 2015 also showed that the incidence rate of lactose malabsorption with lactose intolerance was 27.16% in pediatric patients with gastrointestinal diseases. Moreover, the highest occurrence was 47.83% in IBS, and the lowest was 15.78% of ulcer disease. IBS represents a significant burden on the US and globally, with an estimated prevalence rate of 14%. From all the information, it is observed that the escalating cases of IBS and other gastrointestinal disorders would boost the US lactose intolerance treatment market
Â

Lactose Intolerance Treatment Market Segment Insights
Global Lactose Intolerance Treatment Market is segmented into Type, Treatment, Form, and End User.
Lactose Intolerance Treatment Type Insights
Global Lactose Intolerance Treatment Market based on the type has been segmented into primary lactose intolerance, secondary lactose intolerance, congenital lactose intolerance. Primary lactose intolerance dominated the market in 2022. Primary lactose intolerance has a high prevalence rate as compared to others.Â
Lactose Intolerance Treatment Insights
The global lactose intolerance treatment market, by treatment, has been segmented into food supplements, enzyme lactase supplements, probiotics. The food supplements segment held the largest market share in 2022. The growing adoption of Lactose-free products is fueling the market growth of this segment.Â
Lactose Intolerance Treatment Form Insights
Based on form, the market has been segmented into powder, liquid, tablet. The powder segment dominated the market in 2022.Â
Lactose Intolerance Treatment End User Insights
The global lactose intolerance treatment market, by end user, has been segmented into homecare, hospitals and clinics, and others. The homecare held the largest share with a CAGR of 6.04%.
Lactose Intolerance Treatment Regional Insights
Global Lactose Intolerance Treatment Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas has been segmented into North America and Latin America, with the North America market further divided into the US and Canada. The Americas spearheaded the market in 2022 and is likely to continue to command during the assessment period. This is attributed to the rising incidence of lactose intolerance and product innovation.
The European lactose intolerance treatment market has been divided into Western Europe and Eastern Europe. The Western Europe lactose intolerance treatment market has further been classified into Germany, France, the UK, Italy, Spain, and the Rest of Western Europe. Europe would follow the Americas during the forecast period owing to the presence of favorable government initiatives, research and development activities, and business expansions by major players.
The lactose intolerance treatment market in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia-Pacific. Asia-Pacific is expected to exhibit the highest market growth potential during the forecast period due to increasing healthcare expenditure, distribution of chilled dairy products in China, India, and Australia, and increasing population suffering from lactose intolerance.
The Middle East & Africa lactose intolerance treatment market is segmented into the Middle East and Africa. The Middle East and Africa are highly obsolescence with per capita spend on dairy at just USD 25 per head, the lowest in the world. The underdeveloped infrastructural chain of the region makes it very difficult for the manufacturers to reach their consumers. However, if the affordability rate improves, the growth of the market would be even more dynamic.
Lactose Intolerance Treatment Market Top Key Players
The Prominent Players in the Global Lactose Intolerance Treatment Market are:
-
Abbott (US)
- Nestlé (Switzerland)
- Cargill, Incorporated (US)
- Dean Foods (US)
- Johnson & Johnson Services, Inc. (US)
Lactose Intolerance Treatment Market Industry Developments
-
Q2 2024: Danone launches new dairy-free probiotic supplement for lactose intolerance Danone announced the launch of a new dairy-free probiotic supplement specifically formulated to aid individuals with lactose intolerance, expanding its health-focused product portfolio.
-
Q1 2024: Nestlé Health Science introduces expanded range of lactose-free nutritional products Nestlé Health Science unveiled an expanded line of lactose-free nutritional products targeting consumers with lactose intolerance, aiming to strengthen its position in the specialized nutrition market.
-
Q2 2024: Lactaid opens new manufacturing facility in Ohio to meet rising demand Lactaid, a leading brand in lactose-free dairy products, inaugurated a new manufacturing facility in Ohio to increase production capacity and address growing consumer demand for lactose intolerance solutions.
-
Q3 2024: Johnson & Johnson acquires biotech startup developing enzyme therapy for lactose intolerance Johnson & Johnson completed the acquisition of a biotechnology startup focused on developing novel enzyme therapies for lactose intolerance, aiming to enhance its gastrointestinal health portfolio.
-
Q2 2025: Abbott receives FDA approval for new lactose intolerance diagnostic kit Abbott announced that it has received FDA approval for its new diagnostic kit designed to rapidly detect lactose intolerance in clinical settings.
-
Q1 2025: Arla Foods partners with biotech firm to develop next-generation lactase supplements Arla Foods entered into a strategic partnership with a biotechnology company to co-develop advanced lactase enzyme supplements for improved lactose digestion.
-
Q2 2024: GSK launches chewable lactase tablets for children with lactose intolerance GlaxoSmithKline introduced a new line of chewable lactase tablets formulated for pediatric use, targeting children diagnosed with lactose intolerance.
-
Q3 2024: Chobani debuts plant-based yogurt line for lactose-intolerant consumers Chobani launched a new plant-based yogurt line specifically marketed to consumers with lactose intolerance, expanding its alternative dairy offerings.
-
Q1 2025: LactEase files for IPO to fund expansion of lactose intolerance treatment products LactEase, a company specializing in lactose intolerance treatment products, filed for an initial public offering to raise capital for product development and market expansion.
-
Q2 2025: DSM secures EU regulatory approval for novel lactase enzyme supplement DSM received regulatory approval from the European Union for its new lactase enzyme supplement, enabling commercial distribution across EU member states.
Lactose intolerance Treatment Market Segmentation
Lactose intolerance Treatment Type Outlook
- Primary Lactose Intolerance
- Secondary Lactose Intolerance
- Congenital/Developmental Lactose Intolerance
Lactose intolerance Treatment Outlook
- Food Supplements
- Enzyme Lactase Supplements
- Probiotics
- Others
Lactose intolerance Treatment Form Outlook
- Powder
- Liquid
- Tablets/Capsules
Lactose intolerance Treatment End User Outlook
- Home Care
- Hospitals & Clinics
Lactose intolerance Treatment Regional Outlook
-
Europe
- Western Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Western Europe
-
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Available Additional Customizations
- Impact of COVID-19 on Lactose intolerance Treatment Market
- Mega Trends in the Market
- Investment Opportunities
- Pricing Analysis
Intended Audience
- Hospitals
- Clinics
- Academic institutes
Attribute/Metric |
Details |
Market Size 2030 |
26.12 (USD Billion) |
Compound Annual Growth Rate (CAGR) |
5.9 % ( 2023 -2030) |
  Base Year |
  2022 |
  Forecast Period |
  2023 -2030 |
  Historical Data |
  2021 |
  Forecast Units |
  Value (USD Billion) |
  Report Coverage |
  Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
  Segments Covered |
  Type, Treatment, Form, and End User |
  Geographies Covered |
  North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
  Key Vendors |
  Abbott (US)., Nestlé (Switzerland), Cargill, Incorporated (US), Dean Foods (US), and Johnson & Johnson Services, Inc. (US) |
  Key Market Opportunities |
  Infrastructural chain |
  Key Market Drivers |
  Growing prevalence of lactose intolerance |
Lactose Intolerance Treatment Market Highlights:
Frequently Asked Questions (FAQ):
lactose intolerance treatment market is expected to be valued at more than USD 26.12 billion by 2030.
The global market is expected to exhibit a strong 5.90% CAGR over the forecast period from 2023 to 2030.
The growing prevalence of lactose intolerance is the major driver for the market.
Europe held a dominant 42% share in the global lactose intolerance treatment market in 2018.
Leading players in the market include Abbott, Nestle, and Cargill Inc., among others.